Global pharmaceutical giants Eli Lilly and Novo Nordisk are locked in an intense battle to dominate India's rapidly growing weight-loss drug market before low-cost generics flood in. With the obesity drug market in the world's most populous nation projected to surpass $1 billion within two years, both companies are employing aggressive tactics—including steep price cuts, accelerated product launches, and Bollywood celebrity endorsements—to solidify their foothold.
According to reports, Novo Nordisk has slashed the price of its weight-loss drug Wegovy by approximately 37% in November and fast-tracked the rollout of its blockbuster diabetes drug Ozempic to counter Eli Lilly’s early-mover advantage with Mounjaro. Vikrant Shrotriya, Managing Director of Novo Nordisk India, acknowledged that price reductions were necessary to improve accessibility and compete in this cost-sensitive market.
Eli Lilly, meanwhile, is leveraging its first-mover status and high-profile branding. Despite maintaining higher prices for Mounjaro—which claims superior weight-loss efficacy—the company leads in sales volume, backed by social media campaigns featuring Bollywood stars and obesity-awareness advertisements.
The rivalry is fueled by an impending patent cliff. Over 20 Indian generics makers, including Dr. Reddy’s, Cipla, and Sun Pharma, are preparing to launch copycat versions at 60% lower prices once Novo Nordisk’s key patent expires in March 2026. This has forced both multinationals to deepen brand loyalty through expanded distribution networks and patient education in smaller cities.
**Price War and First-Mover Edge** While the U.S. remains the largest market, India’s early sales growth is staggering. Eli Lilly’s Mounjaro, approved for diabetes and weight loss in March, quickly became India’s top-selling therapy by value, with sales doubling within months. Novo Nordisk retaliated by cutting Wegovy’s lowest-dose price to ₹10,850 ($121) monthly and introducing Ozempic at ₹8,800 ($98)—undercutting Mounjaro’s ₹13,125–25,781 ($147–288) range.
Dr. Anoop Misra of Fortis C-DOC noted price-sensitive patients are reconsidering options, though analysts say Mounjaro’s efficacy for severe obesity insulates it from immediate pricing pressure.
**Generic Onslaught Looms** The biggest threat stems from India’s generics pipeline. Over 20 local firms aim to launch semaglutide (Wegovy/Ozempic’s active ingredient) copies post-patent expiry. Novo Nordisk has sued Dr. Reddy’s and Sun Pharma to block early generics, while Eli Lilly benefits from tirzepatide (Mounjaro)’s patent protection extending into the next decade.
**Expanding Reach and Marketing Blitz** Both firms are partnering with local players to penetrate smaller towns. Eli Lilly allied with Cipla for its second tirzepatide brand, Yurpeak, and invested $1B+ in Indian manufacturing. Novo Nordisk teamed with Emcure for semaglutide brand Poviztra, while circumventing India’s direct-to-consumer ad ban via disease-awareness campaigns like "WeGoWithYou."
**A $1B Battleground** India’s obesity drug market, valued at ₹6.28B ($70M) in July—a fivefold jump since 2021—is poised to exceed $1B by 2026. Despite most patients paying out-of-pocket, the country’s projected status as the world’s second-largest obese population by 2050 makes it a critical growth engine for the global weight-loss drug industry, forecast to hit $150B annually by 2030.
Comments